CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Gr. Inc. Y/Y Annual
Rigel Pharmaceuticals Inc  (RIGL)
Other Ticker:  
 
 

RIGL's Gross Income Growth by Quarter and Year

Rigel Pharmaceuticals Inc's Gross Income results by quarter and year




RIGL Gross Income (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December - 50.94 19.92 18.13
III Quarter September 26.87 22.16 21.39 18.25
II Quarter June 25.81 28.78 26.14 15.74
I Quarter March 25.09 16.61 80.70 55.61
FY   77.77 118.49 148.15 107.73



RIGL Gross Income third quarter 2023 Y/Y Growth Comment
Rigel Pharmaceuticals Inc achieved in the third quarter 2023, above Company average Gross Income growth of 21.24% year on year, to $ 26.87 millions.

Looking into third quarter 2023 results within Major Pharmaceutical Preparations industry 123 other companies have achieved higher Gross Income growth. While Rigel Pharmaceuticals Inc' s Gross Income rise of 21.24% ranks overall at the positon no. 2184 in the third quarter 2023.

Explain Gross Income Margin


RIGL Gross Income ( Y/Y Growth %) 2023
 2022 2021 2020
IV Quarter December - 155.72 % 9.87 % 19.12 %
III Quarter September 21.24 % 3.6 % 17.21 % -11.19 %
II Quarter June -10.32 % 10.1 % 66.07 % 55.84 %
I Quarter March 51.05 % -79.42 % 45.12 % 344.17 %
FY   - -20.02 % 37.52 % 84.5 %

Financial Statements
Rigel Pharmaceuticals Inc's third quarter 2023 Gross Income $ 26.87 millions RIGL's Income Statement
Rigel Pharmaceuticals Inc's third quarter 2022 Gross Income $ 22.16 millions Quarterly RIGL's Income Statement
New: More RIGL's historic Gross Income Growth >>


RIGL Gross Income (Quarter on Quarter Growth %)

 2023
 2022 2021 2020
IV Quarter December - 129.87 % -6.87 % -0.66 %
III Quarter September 4.09 % -23 % -18.17 % 15.95 %
II Quarter June 2.87 % 73.27 % -67.61 % -71.7 %
I Quarter March -50.75 % -16.62 % 345.12 % 265.37 %
FY (Year on Year)   - -20.02 % 37.52 % 84.5 %


Compare RIGL Profitability >> Back to RIGL Growth rate Comparisons >>


Gross Income third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #124
Healthcare Sector #337
Overall #2184

Gross Income Y/Y Growth Statistics
High Average Low
84.52 % 17.71 % -40.35 %
(Dec 31 2020)   (Mar 31 2017)
Gross Income third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #124
Healthcare Sector #337
Overall #2184
Gross Income Y/Y Growth Statistics
High Average Low
84.52 % 17.71 % -40.35 %
(Dec 31 2020)   (Mar 31 2017)

Gross Income by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Rigel Pharmaceuticals Inc's Q/Q Gross Income Growth


Gross Income Q/Q Growth Statistics
High Average Low
703.29 % 33.38 % -100 %
(Dec 31 2018)  


RIGL's III. Quarter Q/Q Gross Income Comment
Rigel Pharmaceuticals Inc achieved in the III. Quarter 2023 below company average Gross Income growth of 4.09% quarter on quarter, to $ 26.87 millions.

Albeit the III. Quarter 2023 Rigel Pharmaceuticals Inc's results were lower than the ordinary of 33.38 %, this has been still promising sign, as the III. Quarter improvement, transcends the -23% Gross Income rise in the same quarter a year ago

Within Major Pharmaceutical Preparations industry 115 other companies have achieved higher Gross Income quarter on quarter growth. While Rigel Pharmaceuticals Inc's Gross Income growth quarter on quarter, overall rank is 1423.


Gross Income Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #116
Healthcare Sector #258
Overall #1423
Gross Income Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #116
Healthcare Sector #258
Overall #1423
Gross Income Q/Q Growth Statistics
High Average Low
703.29 % 33.38 % -100 %
(Dec 31 2018)  


RIGL's III. Quarter Q/Q Gross Income Comment
Rigel Pharmaceuticals Inc achieved in the III. Quarter 2023 below company average Gross Income growth of 4.09% quarter on quarter, to $ 26.87 millions.

III. Quarter 2023 performance were contradictory, even if beneath the ordinary, yet it demonstrates a quite recovery compare to the -23% in the III. Quarter 2022 Élise Lambert, Major Pharmaceutical Preparations industry researcher located in Brussel mentioned.

Within Major Pharmaceutical Preparations industry 115 other companies have achieved higher Gross Income quarter on quarter growth. While Rigel Pharmaceuticals Inc's Gross Income growth quarter on quarter, overall rank is 1423.


Rigel Pharmaceuticals Inc's 12 Months Gross Income Growth Year on Year


Gross Income TTM Growth

12 Months Ending
(Sep 30 2023)		 12 Months Ending
(Jun 30 2023)		 12 Months Ending
(Mar 31 2023)		 12 Months Ending
(Dec 31 2022)		 12 Months Ending
(Sep 30 2022)
Cumulative Gross Income 12 Months Ending $ 128.71 $ 124.00 $ 126.97 $ 118.49 $ 87.48
Y / Y Gross Income Growth (TTM) 47.13 % 43 % 51.04 % -20.02 % -40.23 %
Year on Year Gross Income Growth Overall Ranking # 3263 # 2949 # 3209 # 833 # 0
Seqeuential Gross Income Change (TTM) 3.8 % -2.34 % 7.16 % 35.45 % 0.89 %
Seq. Gross Income Growth (TTM) Overall Ranking # 2193 # 1978 # 3246 # 2435 # 0

New: More RIGL's historic Gross Income Growth >>



Cumulative Gross Income growth Comment
Rigel Pharmaceuticals Inc saw improvement in Gross Income growth trend, posting cumulative 12 months Gross Income growth of 47.13% year on year, to $ 129 millions if the fiscal year would have ended in Sep 30 2023.
Rigel Pharmaceuticals Inc's trailing twelve months Gross Income growth was higher than company's average 17.71% and higher than 43% growth in Jun 30 2023.
But from the previous reporting period increase was less at 3.8 % from $124 millions achieved in twelve months ending a quarter Jun 30 2023 Élise Lambert added on.
It appears to be drop-off developing, more evident observing the usual sequential Gross Income increase that is better at17.71% Élise Lambert published.
The momentum was even stronger from twelve months ended Jun 30 2023 exhibited at 3.8 % increase from $124 millions in the period from Jun 30 2023 to Sep 30 2022.

In the Healthcare sector 466 other companies have achieved higher trailing twelve month Gross Income growth. While Gross Income growth total ranking has deteriorated compare to previous quarter from 2949 to 3263.

Gross Income TTM Q/Q Growth Statistics
High Average Low
84.52 %
17.71 %
-40.35 %
 

Gross Income TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 124
Healthcare Sector # 467
Overall # 3263

Gross Income TTM Y/Y Growth Statistics
High Average Low
84.52 %
17.71 %
-40.35 %
 


Gross Income TTM Q/Q Growth Company Ranking
Within: No.
Industry # 124
Sector # 339
S&P 500 # 2193
Cumulative Gross Income growth Comment
Rigel Pharmaceuticals Inc saw improvement in Gross Income growth trend, posting cumulative 12 months Gross Income growth of 47.13% year on year, to $ 129 millions if the fiscal year would have ended in Sep 30 2023.
Rigel Pharmaceuticals Inc's trailing twelve months Gross Income growth was higher than company's average 17.71% and higher than 43% growth in Jun 30 2023.
But sequential rise was slower at 3.8 % from $124 millions recorded in twelve months ending a quarter Jun 30 2023.
It appears to be stagnation happening, more noticeable as we look at usual Q/Q TTM Gross Income advancement what is better at17.71% Élise Lambert wrote.
The growth was much stronger sequentially clinched at 3.8 % jump from $124 millions in twelve months ending a quarter before.

In the Healthcare sector 466 other companies have achieved higher trailing twelve month Gross Income growth. While Gross Income growth total ranking has deteriorated compare to previous quarter from 2949 to 3263.

Gross Income TTM Q/Q Growth Statistics
High Average Low
84.52 %
17.71 %
-40.35 %
 


Gross Income TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 124
Healthcare Sector # 467
Overall # 3263

Gross Income TTM Y/Y Growth Statistics
High Average Low
84.52 %
17.71 %
-40.35 %
 


Gross Income TTM Q/Q Growth Company Ranking
Within: No.
Industry # 124
Sector # 339
S&P 500 # 2193




Other Gross Income Growth
Major Pharmaceutical Preparations Industry Gross Income Growth Trends and Statistics
Healthcare Sector Gross Income Growth Statistics
Gross Income Growth Trends for overall market
RIGL's Gross Income Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Gross Income Growth
Lowest Ranking Gross Income Growth
Gross Income Growth for RIGL's Competitors
Gross Income Growth for Rigel Pharmaceuticals Inc's Suppliers
Gross Income Growth for RIGL's Customers

You may also want to know
RIGL's Annual Growth Rates RIGL's Profitability Ratios RIGL's Asset Turnover Ratio RIGL's Dividend Growth
RIGL's Roe RIGL's Valuation Ratios RIGL's Financial Strength Ratios RIGL's Dividend Payout Ratio
RIGL's Roa RIGL's Inventory Turnover Ratio RIGL's Growth Rates RIGL's Dividend Comparisons



Companies with similar Gross Income growth for the quarter ending Sep 30 2023 within Healthcare SectorY/Y Change %Gross Income for the quarter ending Sep 30 2023
Amicus Therapeutics inc 37.07%$ 37.067 millions
Collegium Pharmaceutical Inc 36.49%$ 36.493 millions
Progyny Inc 36.15%$ 36.154 millions
Harmony Biosciences Holdings inc 35.78%$ 35.784 millions
Lantheus Holdings Inc 35.62%$ 35.622 millions
Axonics Inc 34.81%$ 34.811 millions
Alphatec Holdings Inc 34.50%$ 34.497 millions
Guardion Health Sciences Inc 34.19%$ 34.192 millions
Myomo Inc 32.30%$ 32.304 millions
Pacific Biosciences Of California Inc 32.15%$ 32.147 millions
Sanara Medtech Inc 31.97%$ 31.967 millions
Globus Medical Inc 31.59%$ 31.592 millions
Inari Medical Inc 31.42%$ 31.418 millions
Penumbra Inc 31.32%$ 31.325 millions
Urogen Pharma Ltd 31.31%$ 31.313 millions
Cardiff Lexington Corporation30.63%$ 30.635 millions
Adaptimmune Therapeutics Plc29.15%$ 29.150 millions
Talkspace Inc 29.15%$ 29.147 millions
Msa Safety Incorporated29.14%$ 29.143 millions
Igc Pharma Inc 28.89%$ 28.889 millions
Deciphera Pharmaceuticals Inc 28.80%$ 28.799 millions
The Oncology Institute Inc 28.50%$ 28.502 millions
Pulmonx Corporation28.34%$ 28.339 millions
Select Medical Holdings Corp28.28%$ 28.284 millions
Liquidia Corporation28.16%$ 28.165 millions
Neurocrine Biosciences Inc 27.71%$ 27.711 millions
Natera inc 27.46%$ 27.461 millions
Lifemd Inc 26.73%$ 26.734 millions
Myriad Genetics Inc 26.70%$ 26.698 millions
Dexcom Inc 26.12%$ 26.123 millions


Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com